2026-10-10T04:10:31Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33771886 2026-09-15T05:36:38Z category_19 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Efficacy and safety of first-line immunotherapy-related induction and maintenance therapy for extensive-stage small cell lung cancer: a systematic review and Bayesian network meta-analysis.docx Hong-Jing Yu (24912712) Jun-Chen Liu (24912715) Dong-Sheng Zhang (226836) Zhi Chen (222749) Qi Deng (314917) Pharmacology Bayesian network meta-analysis efficacy and safety extensive-stage small cell lung cancer first-line therapy immune checkpoint inhibitors Background<p>Extensive-stage small cell lung cancer (ES-SCLC) is highly aggressive with dismal prognosis, and platinum monochemotherapy offers modest long-term survival. Multiple first-line regimens integrating immunotherapy, anti-angiogenic agents and chemotherapy have been approved, yet direct head-to-head comparisons are scarce, and the optimal induction plus maintenance strategy remains undefined. In this study, a Bayesian network meta-analysis (NMA) was performed to hierarchically assess the efficacy and safety of available first-line regimens and identify balanced treatment strategies for ES-SCLC.</p>Methods<p>Eligible phase III randomized controlled trials (RCTs) were identified by searching PubMed, Embase, the Cochrane Library, and Web of Science. Trials were included if they enrolled treatment-naïve patients with ES-SCLC and reported at least one of the following outcomes: overall survival (OS), progression-free survival (PFS), or grade ≥3 treatment-related adverse events (TRAEs). NMA was implemented using the gemtc package in R. SUCRA values were calculated for treatment ranking, and subgroup analyses stratified by pharmacological mechanisms were conducted.</p>Results<p>Fourteen RCTs involving 8,945 patients across 18 regimens were included in the present analysis. These trials encompassed diverse combinations of mainstream immune checkpoint inhibitors, anti-angiogenic targeted agents, and chemotherapeutic agents. The atezolizumab + lurbinectedin + chemotherapy and benmelstobart + anlotinib + chemotherapy regimens showed the greatest potential for superior PFS and OS compared with chemotherapy alone. Subgroup analyses confirmed sustained efficacy benefits for PD-L1 inhibitor-based triple-combination strategies. The nivolumab + ipilimumab regimen was associated with the highest risk of severe toxicity.</p>Conclusion<p>PD-L1 inhibitor combined with platinum-based chemotherapy together with anti-angiogenic agents or lurbinectedin conferred optimal survival benefits, yet toxicity was correspondingly augmented. This study provides valuable insights into therapeutic drug selection for ES-SCLC.</p>Systematic Review Registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD420261402898, identifier 420261402898.</p> 2026-09-15T05:36:38Z Dataset Dataset 10.3389/fphar.2026.1944817.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Efficacy_and_safety_of_first-line_immunotherapy-related_induction_and_maintenance_therapy_for_extensive-stage_small_cell_lung_cancer_a_systematic_review_and_Bayesian_network_meta-analysis_docx/33771886 CC BY 4.0